Baxter (BAX) Tops Q3 EPS by 10c, Offers FY Guidance
Get Alerts BAX Hot Sheet
Price: $39.65 --0%
Revenue Growth %: -2.7%
Financial Fact:
Other expense, net: 44M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: -2.7%
Financial Fact:
Other expense, net: 44M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Baxter (NYSE: BAX) reported Q3 EPS of $0.83, $0.10 better than the analyst estimate of $0.73. Revenue for the quarter came in at $2.97 billion versus the consensus estimate of $2.83 billion.
GUIDANCE:
Baxter sees FY2020 EPS of $3.02-$3.05, versus the consensus of $3.06.
- For full-year 2020, Baxter expects sales growth compared to the prior-year period to be up low single digits on a reported, constant currency and operational basis. The company expects U.S. GAAP earnings of $2.41 to $2.44 per share and adjusted earnings, before special items, of $3.02 to $3.05 per share. This outlook assumes, among other things, low double digit declines in hospital admissions and mid-single digit declines in surgical volumes in the fourth quarter 2020 as compared to pre-COVID levels.
For earnings history and earnings-related data on Baxter (BAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- JD.com, Inc (JD) PT Lowered to $25 at Morgan Stanley
- Senesco Technologies, Inc. (SNT) Reports Q1 EPS of $0.02
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!